Integrated Molecular Subtyping of Clinical Metastasis: Implications for Defining a Curable Oligometastatic State
Pitroda S, Khodarev N, Huang L, Uppal A, Wightman S, Ganai S, Joseph N, Xue L, Weber C, Segal J, Stack M, Khan S, Paty P, Kaul K, Andrade J, White K, Talamonti M, Posner M, Hellman S, Weichselbaum R. Integrated Molecular Subtyping of Clinical Metastasis: Implications for Defining a Curable Oligometastatic State. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s12. DOI: 10.1016/j.ijrobp.2018.06.122.Peer-Reviewed Original ResearchIntegrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nature Communications 2018, 9: 1793. PMID: 29728604, PMCID: PMC5935683, DOI: 10.1038/s41467-018-04278-6.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesLiver metastasesColorectal cancerOligometastatic colorectal cancerMetastatic colorectal cancerHigh-risk patientsSubset of patientsClinical risk stratificationTreatment of metastasesAngiogenic signatureVEGFA amplificationOligometastatic stateOverall survivalFavorable survivalRisk stratificationAdverse outcomesMetastatic cancerMolecular subtypesFocal therapyMetastasisPatientsMetastatic virulenceMolecular subtypingRobust subtypesCancer